Post-acute sequalae of Coronavirus disease-19 (COVID-19 [PASC]) are defined as the persistence of existing or new symptoms for a period extending beyond initial COVID-19 infection. Post COVID Neurological Syndrome (PCNS) relates to the persistent cognitive and neurological deficits characteristic of PASC. This includes significant changes in attention and memory function in adult and geriatric populations, with such impairments notably impacting quality of life. However, despite reports of similar cognitive changes in paediatric patients, this issue is yet to be systematically investigated. This systematic review and meta-analysis synthesised literature reporting on the prevalence of clinically significant cognitive impairment in paediatric PASC using DSM-5 cognitive domains to categorise study outcomes. Final literature searching was completed on 15th of November, 2024 across four databases combining the following keywords: ‘COVID-19’, ‘cognition’ and ‘paediatric’. Included studies examined standardised psychometric or parent report measures of cognition in children and adolescents with a PASC diagnosis. Studies were excluded if participants had prior cognitive impairments or comorbidities. Risk of bias was assessed using Joanna Briggs Institute Critical Appraisal Tool’s Checklist for Analytical Cross-sectional Studies. Results revealed that between 35-55% of paediatric PASC patients were ‘at risk of impairment’ or showed ‘clinically significant’ impairment in complex attention, learning and memory, working memory and executive function. Further research is needed to assess impacts of infection severity and repeated infection. However, this meta-analysis provides insights into the nature of PCNS-associated complications to aid more detailed management strategies for children and adolescents.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used only openly available human data obtained from original research articles indexed in PubMED, Ovid Medline, Ovid Embase and Web of Science databases.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript.